Q. Liu, L. Hou, Y. Zhao, H. Yang, Z. Mo, and F. Yu, “Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer”, Clinics, vol. 78, p. 100291, May 2023, doi: 10.1016/.